There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Dexcom (DXCM – Research Report) and Baxter International (BAX – Research Report) with bullish sentiments.
Dexcom (DXCM)
In a report issued on June 24, Marie Thibault from BTIG maintained a Buy rating on Dexcom, with a price target of $105.00. The company’s shares closed last Friday at $77.67, close to its 52-week low of $66.89.
According to TipRanks.com, Thibault is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Dexcom with a $117.23 average price target, representing a 53.6% upside. In a report issued on June 16, Atlantic Equities also maintained a Buy rating on the stock with a $125.00 price target.
See today’s best-performing stocks on TipRanks >>
Baxter International (BAX)
J.P. Morgan analyst Robbie Marcus maintained a Buy rating on Baxter International on June 24 and set a price target of $78.00. The company’s shares closed last Friday at $66.78, close to its 52-week low of $63.25.
According to TipRanks.com, Marcus is a 4-star analyst with an average return of
Baxter International has an analyst consensus of Moderate Buy, with a price target consensus of $86.45.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on DXCM:
